O principal objetivo deste trabalho é fornecer um modelo biocinético validado em termos fisiológicos para a avaliação das doses radiométricas devido à ingestão de [4-14C]-colesterol em humanos. Com o intuito de validar o modelo biocinético proposto para o [4-14C]-Colesterol, os valores de excreção fecal e absorção preditos pelo modelo foram comparados com dados experimentais da literatura, foi obtido um alto grau de concordância entre os resultados de acordo com teste ANOVA (p = 0,416 para os valores de excreção e p = 0,423 para os valores de absorção). Foram calculados os coeficientes de Dose Efetiva (SvBq-1), Dose Equivalente (SvBq-1) e Dose Absorvida (GyBq-1) nos orgãos e tecidos para humanos utilizando a metodologia MIRD e o software de análise compartimental ANACOMP para quatro objetos simuladores que representam: um adulto com massa de 73,3 kg, um adolescente de 15 anos (56,9 kg), uma criança de 10 anos (33,2 kg) e uma criança de cinco anos (19,8 kg). O órgão que obteve a maior Dose Absorvida, para todos os objetos simuladores, foi o intestino grosso inferior (IGI). O conceito da alometria foi utilizado para interpolar o Coeficiente de Dose Absorvida no intestino grosso inferior (DIGI) para massas corpóreas (m) desconhecidas: DIGI(SvBq-1)=161,26.m(kg)-1,025. Para uma mesma quantidade administrada de colesterol, o Coeficiente de Dose Efetiva (E) diminui com o aumento da massa corporal do objeto simulador, em outras palavras, para a mesma atividade administrada os indivíduos com menor massa são submetidos a Doses Efetivas mais elevadas. O conceito de alometria também foi utilizado para interpolar o Coeficiente de Dose Efetiva (E) para massas corpóreas (m) desconhecidas: E(SvBq-1)= 171,1.m(kg)-1,021. / The main objective of this work is to provide a biokinetic model in order to estimate the radiometric dose due to intake of [4-14C]-cholesterol. The model was validated comparing the values of fecal excretion and absorption described in literature with that predicted by the model. The proposed model achieved good concordance between the results (p = 0.416 for excretion and p = 0.423 for absorption). The coefficients of Effective Dose (SvBq-1), Equivalent Dose (SvBq-1) and Absorbed Dose (GyBq-1) in human organs and tissues were calculated using the MIRD methodology and the compartimental analysis software ANACOMP. The coefficients were estimated for four phantoms: (i) adult with a body mass of 73.3 kg, (ii) 15 years old adolescent (56.9 kg), (iii) 10 years old child (33.2 kg) and (iv) five years old child (19.8 kg). The organ that received the highest Absorbed Dose for all phantoms was the lower large intestine (LLI). The allometry theory was used to interpolate the coefficient of absorbed dose in the lower large intestine (DLLI) for unknown body mass (m): DLLI (GyBq-1)=161.26 m (kg)-1.025. For the same administered activity, the Effective Dose Coefficient (E) decreases as the body mass increases. On other words, for the same intake activity, individuals with low body mass are exposed to higher doses. The allometry theory was used to interpolate the coefficient Effective Dose (E) for unknown body mass (m): E(SvB-1)= 171.1 m(kg)-1,021.

Large-scale radiological accidents have resulted in intakes of radioactive materials by members of the public and occupational radiation workers. However, current methods to evaluate intakes are designed for small numbers of individuals and cannot be easily scaled for large populations as has occurred. A proposed method for high throughput volumes of people to identify and quantify intakes of radioactive material through urine radiobioassay is described. MATERIALS AND METHODS: The MCNP V6.0 software code was used to model the General Electric Hawkeye V3 Gamma Camera for gamma ray efficiency. Technitium-99m was used to validate the model. The model was used to calculate detection efficiencies and minimum detectable doses for Cobalt-60, Iodine-131, Cesium-137/Barium-137m and Iridium-192. RESULTS: Differences of 8% were observed between measurements of the detection efficiency for Technitium-99m and the MCNP modeled detection efficiency (11.1% vs. 12.0%, respectively). Calculations showed that a dose of 20 mSv could be detected using urine radiobioassay in 6, 3, 2, and 20 days post incident for Type F intakes of Cobalt-60, Iodine-131, Cesium-137/Barium-137m and Iridium-192 respectively. Approximately 1,152 urine samples could be analyzed in an eight-hour shift using a single gamma camera. CONCLUSIONS: The use of the gamma camera for urine radiobioassay allows for high throughput volumes of samples and has sufficient detection sensitivity to meet dose-based decision guidelines.

Overexpression of monocarboxylate transporters (MCTs) has been shown for a variety of human cancers (e.g., colon, brain, breast, and kidney) and inhibition resulted in intracellular lactate accumulation, acidosis, and cell death. Thus, MCTs are promising targets to investigate tumor cancer metabolism with positron emission tomography (PET). Here, the organ doses (ODs) and the effective dose (ED) of the first 18F-labeled MCT1/MCT4 inhibitor were estimated in juvenile pigs. Whole-body dosimetry was performed in three piglets (age: ~6 weeks, weight: ~13–15 kg). The animals were anesthetized and subjected to sequential hybrid Positron Emission Tomography and Computed Tomography (PET/CT) up to 5 h after an intravenous (iv) injection of 156 ± 54 MBq [18F]FACH. All relevant organs were defined by volumes of interest. Exponential curves were fitted to the time–activity data. Time and mass scales were adapted to the human order of magnitude and the ODs calculated using the ICRP 89 adult male phantom with OLINDA 2.1. The ED was calculated using tissue weighting factors as published in Publication 103 of the International Commission of Radiation Protection (ICRP103). The highest organ dose was received by the urinary bladder (62.6 ± 28.9 µSv/MBq), followed by the gall bladder (50.4 ± 37.5 µSv/MBq) and the pancreas (30.5 ± 27.3 µSv/MBq). The highest contribution to the ED was by the urinary bladder (2.5 ± 1.1 µSv/MBq), followed by the red marrow (1.7 ± 0.3 µSv/MBq) and the stomach (1.3 ± 0.4 µSv/MBq). According to this preclinical analysis, the ED to humans is 12.4 µSv/MBq when applying the ICRP103 tissue weighting factors. Taking into account that preclinical dosimetry underestimates the dose to humans by up to 40%, the conversion factor applied for estimation of the ED to humans would rise to 20.6 µSv/MBq. In this case, the ED to humans upon an iv application of ~300 MBq [18F]FACH would be about 6.2 mSv. This risk assessment encourages the translation of [18F]FACH into clinical study phases and the further investigation of its potential as a clinical tool for cancer imaging with PET.